AVTX vs USB · P/E 0.0, rev $441.0K vs P/E 12, rev $28.66B
Avalo Therapeutics Inc (AVTX) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the AVTX and USB stock pages for the full models.
Not investment advice.